...exacerbations across both treatment groups and explain the difference between HI-H002 and HI-H005. In April, Bioxyne...
...other indications. In March, Probiomics Ltd. completed its acquisition of Hunter Immunology Ltd. to form Bioxyne...
...April 2). At March 31, the merged entity had A$2.5 million ($2.6 million) in cash. Bioxyne Ltd....

...drug Xiapex collagenase clostridium histolyticum that finds no additional benefit because the dossier was incomplete Bioxyne Ltd....

...is an enteric-coated tablet containing 45 mg of formalin inactivated Haemophilus influenzae . On Thursday, Bioxyne...

...Exchange (ASX) and implemented a 1-for-20 share consolidation. The surviving entity, which will be renamed Bioxyne Ltd....
...the ASX on April 4 (see BioCentury, Jan. 2). Hunter Immunology Ltd. , Sydney, Australia Probiomics...

...Hunter's board recommended that shareholders accept an October merger offer from probiotics company Probiomics. The stock...
...June 30, 2011. The deal, which is subject to Probiomics shareholder approval as well as Probiomics...
...the merger, the surviving entity will be renamed Bioxyne Ltd. Hunter Immunology Ltd. , Sydney, Australia Probiomics...

...Denmark BNY 12/23/02 Chemgenex OTC CXSFY Australia BNY 12/6/02 Roche OTC RHHBY Switzerland BNY 12/5/02 VRI Biomedical...